High
8.550
Open
8.550
VWAP
8.55
Vol
755.56K
Mkt Cap
79.69M
Low
8.540
Amount
6.46M
EV/EBITDA(TTM)
--
Total Shares
89.63M
EV
669.44M
EV/OCF(TTM)
--
P/S(TTM)
3.61K
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
FY2024Q4
FY2025Q2
312.00K
+2736.36%
--
--
310.60K
+7665%
--
--
0.00
-100%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Chimerix, Inc. (CMRX) for FY2025, with the revenue forecasts being adjusted by -11.89% over the past three months. During the same period, the stock price has changed by 76.81%.
Revenue Estimates for FY2025
Revise Downward
-11.89%
In Past 3 Month
Stock Price
Go Up
+76.81%
In Past 3 Month
5 Analyst Rating
0.00% Downside
Wall Street analysts forecast CMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMRX is 8.54 USD with a low forecast of 8.50 USD and a high forecast of 8.55 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
4 Hold
0 Sell
Hold
0.00% Downside
Current: 8.540
Low
8.50
Averages
8.54
High
8.55
0.00% Downside
Current: 8.540
Low
8.50
Averages
8.54
High
8.55
Jones Trading
Soumit Roy
Strong Buy
to
Hold
Downgrades
$8.55
2025-03-06
Reason
Jones Trading
Soumit Roy
Price Target
$8.55
2025-03-06
Downgrades
Strong Buy
to
Hold
Reason
JonesResearch downgraded Chimerix (CMRX) to Hold from Buy with an $8.55 price target after Jazz Pharmaceuticals (JAZZ) announced a deal to acquire the company for $8.55 per share or $935M in cash.
Jefferies
Maury Raycroft
Strong Buy
to
Hold
Downgrades
$10 → $8.5
2025-03-05
Reason
Jefferies
Maury Raycroft
Price Target
$10 → $8.5
2025-03-05
Downgrades
Strong Buy
to
Hold
Reason
HC Wainwright & Co.
Edward White
Strong Buy
to
Hold
Downgrades
$11
2025-03-05
Reason
HC Wainwright & Co.
Edward White
Price Target
$11
2025-03-05
Downgrades
Strong Buy
to
Hold
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$11
2025-02-18
Reason
HC Wainwright & Co.
Edward White
Price Target
$11
2025-02-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$11
2024-12-30
Reason
HC Wainwright & Co.
Edward White
Price Target
$11
2024-12-30
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$11
2024-12-11
Reason
HC Wainwright & Co.
Edward White
Price Target
$11
2024-12-11
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Chimerix Inc (CMRX.O) is -9.38, compared to its 5-year average forward P/E of -3.85. For a more detailed relative valuation and DCF analysis to assess Chimerix Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.85
Current PE
-9.38
Overvalued PE
47.93
Undervalued PE
-55.62
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.62
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.20
Undervalued EV/EBITDA
-3.44
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
77.18
Current PS
163.58
Overvalued PS
193.97
Undervalued PS
-39.61
Financials
Annual
Quarterly
FY2024Q4
YoY :
+1325.00%
57.00K
Total Revenue
FY2024Q4
YoY :
+17.98%
-24.55M
Operating Profit
FY2024Q4
YoY :
+26.39%
-22.95M
Net Income after Tax
FY2024Q4
YoY :
+25.00%
-0.25
EPS - Diluted
FY2024Q4
YoY :
+33.20%
-19.43M
Free Cash Flow
FY2024Q4
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2024Q4
YoY :
+66.28%
-35.50K
FCF Margin - %
FY2024Q4
YoY :
-91.13%
-40.27K
Net Margin - %
FY2024Q4
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 160.55% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
91.1K
USD
8
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1577.25% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
2.1M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
2
122.8K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 160.55% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
91.1K
USD
8
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CMRX News & Events
Events Timeline
2025-03-21 (ET)
2025-03-21
06:01:39
Chimerix reports Q4 EPS (25c), consensus (28c)
2025-03-05 (ET)
2025-03-05
09:59:11
Chimerix downgraded to Neutral from Buy at H.C. Wainwright
2025-03-05
07:03:37
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash
Sign Up For More Events
Sign Up For More Events
News
2.0
04-07BenzingaTop 3 Health Care Stocks That May Crash In Q2
9.5
03-21SeekingAlphaChimerix GAAP EPS of -$0.25 beats by $0.01, revenue of $0.06M misses by $0.25M
7.0
03-17PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA, CKPT on Behalf of Shareholders
Sign Up For More News
People Also Watch
HYAC
Haymaker Acquisition Corp 4
11.050
USD
0.00%
LFVN
LifeVantage Corp
12.670
USD
+0.88%
NATH
Nathan's Famous Inc
101.800
USD
0.00%
PBPB
Potbelly Corp
10.165
USD
-0.15%
MPX
Marine Products Corp
8.750
USD
+0.46%
GOCO
Gohealth Inc
7.500
USD
0.00%
MVIS
MicroVision Inc
1.078
USD
-2.00%
FSBW
FS Bancorp Inc
40.520
USD
0.00%
XOMA
XOMA Corp
26.740
USD
0.00%
VMD
Viemed Healthcare Inc
6.870
USD
0.00%
FAQ
What is Chimerix Inc (CMRX) stock price today?
The current price of CMRX is 8.54 USD — it has decreased -0.12 % in the last trading day.
What is Chimerix Inc (CMRX)'s business?
What is the price predicton of CMRX Stock?
What is Chimerix Inc (CMRX)'s revenue for the last quarter?
What is Chimerix Inc (CMRX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Chimerix Inc (CMRX)'s fundamentals?
How many employees does Chimerix Inc (CMRX). have?